Disarib was proven to inhibit the growth of Bcl-2 high cancer cell lines and CLL patient primary cell lines with minimum effect on Bcl-2 low cancer cell lines. The gene discussed is BCL2; the disease is B-cell chronic lymphocytic leukemia.